Sign In
Buy ABCL
$5.80
-0.665 (-10.29%)
At Close: Jul 20, 2026
AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment
01:50am, Friday, 22'nd Apr 2022
AbCellera, the stock, has had a woeful two plus years as a public company; however, AbCellera the business is performing brilliantly. The company recently announced an internally developed T-Cell enga
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
04:05pm, Tuesday, 12'th Apr 2022
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q4 2021 Earnings Call Transcript
11:15pm, Thursday, 24'th Feb 2022
Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q4 2021 Earnings Call Transcript
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
04:05pm, Friday, 11'th Feb 2022
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #antibodies--AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm
08:45am, Friday, 11'th Feb 2022
AbCellera announced on Thursday Feb 10th a supply deal with the US government and Lilly for Bebtelovimab, the AbCellera developed pan COVID variant antibody treatment.
AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues
12:17am, Sunday, 05'th Dec 2021
AbCellera has been pummeled in the market this year, dropping like a stone to the current price of just over $14 a share. I believe this is a huge mistake. AbCellera currently has 131 programs with ro
Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q3 2021 Results - Earnings Call Transcript
09:09pm, Tuesday, 09'th Nov 2021
Abcellera Biologics, Inc. (ABCL) CEO Carl Hansen on Q3 2021 Results - Earnings Call Transcript
Why AbCellera Biologics Stock Sank 21.6% in October
10:57am, Thursday, 04'th Nov 2021
The biotech is now down roughly 56% across 2021's trading.
AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy
03:45am, Monday, 18'th Oct 2021
AbCellera shares have been rocked by news of Merck's "COVID pill" treatment, sending shares down 25% from recent highs. In September, AbCellera's current antibody therapy was put back into use after a
Why AbCellera Biologics Stock Jumped 19.4% Last Month
07:59am, Thursday, 07'th Oct 2021
Despite last month's gains, the biotech stock is now down roughly 61% year to date.
AbCellera (ABCL), Everest to Co-Develop New Antibody Therapies
03:18pm, Thursday, 23'rd Sep 2021
AbCellera (ABCL) partners with China-based Everest Medicines to expand the latter???s pipeline across multiple indications.
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
06:00pm, Wednesday, 22'nd Sep 2021
VANCOUVER, British Columbia and SHANGHAI, Sept. 22, 2021 /PRNewswire/ -- AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, "Everest") announced today that they have entered into a
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--Lilly to Supply the EU and EEA with up to 220,000 Doses of Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID
ABCL Stock: Why It Increased Today
08:51am, Friday, 17'th Sep 2021
The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) increased by over 16% pre-market. This is why it happened.
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
06:34am, Friday, 17'th Sep 2021
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent
